Richard Thorn

Title: Richard Thorn: Innovator in Gene Therapy for AADC Deficiency

Introduction

Richard Thorn is a notable inventor based in Mendon, MA (US). He has made significant contributions to the field of gene therapy, particularly in addressing aromatic-amino acid decarboxylase (AADC) deficiency. His innovative approach has the potential to transform treatment options for affected pediatric patients.

Latest Patents

Richard Thorn holds a patent for a groundbreaking invention titled "Gene therapy for AADC deficiency." This patent outlines compositions and methods for treating AADC deficiency, which is a rare genetic disorder. The invention includes a method of treating AADC deficiency in pediatric subjects by providing a pharmaceutical formulation comprising an rAAV2-hAADC vector. The method involves stereotactically delivering the formulation to target sites in the brain, ensuring precise treatment. The patent also discusses the option of administering a therapeutically effective dose of dopamine-antagonist, such as risperidone, to enhance treatment efficacy. Richard Thorn's patent is a significant advancement in the field, with 1 patent to his name.

Career Highlights

Richard Thorn is affiliated with National Taiwan University, where he continues to engage in research and development in gene therapy. His work focuses on innovative solutions for genetic disorders, showcasing his commitment to improving patient outcomes through scientific advancements.

Collaborations

Richard Thorn has collaborated with esteemed colleagues, including Mark Pykett and Wuh-Liang (“Paul”) Hwu. These partnerships have fostered a collaborative environment that enhances the research and development of effective therapies.

Conclusion

Richard Thorn's contributions to gene therapy, particularly for AADC deficiency, highlight his role as an innovator in the medical field. His work not only advances scientific knowledge but also offers hope for patients suffering from this challenging condition.